Cytosine Arabinoside

Phase 3Small molecule

PPETHEMA Foundation

Cytosine Arabinoside is one of 68 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

Langerhans Cell HistiocytosisRecruiting

Acute Myeloid LeukemiaPreclinical

Active, not recruiting

Langerhans Cell HistiocytosisPhase 3

Recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

59 2

Novantrone

Pfizer

Phase 3

34 3

Fludara

Sanofi

Phase 3

17 4

Vepesid

AAvyxa

Phase 3

52 5

Vanflyta

Daiichi Sankyo

Phase 3

14 6

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 7

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

30 8

Nexavar

Bayer

Phase 3

12 9

Busulfex

Trexall

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia3 trials

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Completed·PPETHEMA Foundation·Phase 4·NCT00526305·100 enrolled

Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 2·NCT00199186

LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00526409·40 enrolled

Treatment2 trials

LAL-BR/2001: Study Treatment to Low Risk ALL

Completed·PPETHEMA Foundation·Phase 4·NCT00526175·150 enrolled

PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years

Unknown status·PPETHEMA Foundation·Phase 4·NCT01358201·100 enrolled

Leukemia2 trials

A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)

Completed·NNorthern Italy Leukemia Group·Phase 3·NCT00495287·573 enrolled

High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)

Completed·—·Phase 2·NCT00136448·30 enrolled

Acute Myeloid Leukemia1 trial

Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)

Completed·UUniversity of Rochester·N/A·NCT02101983·11 enrolled

Langerhans Cell Histiocytosis1 trial

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Recruiting·NNorth American Consortium for Histiocytosis·Phase 2/3·NCT02205762·1,400 enrolled

4 more indications

AML1 trial

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

Completed·SSWOG Cancer Research Network·Phase 3·NCT00085709·637 enrolled

Diffuse Large B-Cell Lymphoma1 trial

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Completed·LLymphoma Study Association·Phase 3·NCT00137995·481 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00853008·100 enrolled

Refractory AML1 trial

Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

Completed·—·Phase 1·NCT02891278·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Cytosine Arabinoside. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cytosine Arabinoside compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cytosine Arabinoside. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PETHEMA Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPETHEMA Foundation

Cytosine Arabinoside

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Lymphoblastic Leukemia3 trials

Treatment2 trials

Leukemia2 trials

Acute Myeloid Leukemia1 trial

Langerhans Cell Histiocytosis1 trial

AML1 trial

Diffuse Large B-Cell Lymphoma1 trial

Adult Acute Lymphoblastic Leukemia1 trial

Refractory AML1 trial

References

Drug Info

Quick Facts

Related News